* Glenmark Pharmaceuticals released its Investor Presentation for Q2 FY26 on November 14, 2025. * Q2 FY26 reflects the steady progress the company is making in strengthening Glenmark’s scientific and strategic foundation. * The AbbVie partnership for ISB 2001, along with the income recognized this quarter, is a significant validation of Glenmark's scientific strength and enables advancement of the pipeline in a financially self-sustaining way. * Consolidated Revenue for Q2 FY26 stood at ₹60,469 million, with a YoY growth of 76.1%. * EBITDA stood at ₹23,596 million with an EBITDA margin of 39.0%. * Profit After Tax (PAT) was ₹6,104 million with a PAT margin of 10.1%. * US core business grew by 7.4%, and the EU business grew by 8.5%. * India business was impacted due to GST regime change. * Expect reported growth for India business to normalize from Q3 onwards. * ISB 2001 deal related expenses affected the profits. * Expecting RYALTRIS® to be launched in China and Thailand in forthcoming quarters. * Glenn Saldanha, Chairman and Managing Director, stated that Q2 FY26 reflects the steady progress in strengthening Glenmark’s scientific and strategic foundation. The AbbVie partnership for ISB 2001 enables the company to advance the pipeline in a financially self-sustaining way. The company remains committed to disciplined execution, advancing meaningful science, and delivering sustained value for its patients, partners, and all stakeholders. * H2 FY26 Guidance: Estimated Revenue of >₹80,000 million and EBITDA Margins of ~23%.
